PeptideFactSheetsAn independent reference
Menu

Research peptide blend · Fact sheet

GLOW blend

Also known as GHK-Cu + BPC-157 + TB-500

GLOW blend combines GHK-Cu, BPC-157 and TB-500. Human evidence for the exact blend is not established; studies of individual ingredients do not validate the mixture.

Not FDA approvedLimited or unclear evidence
Skin & hairMuscle & recovery

What is GLOW blend?

GHK-Cu, BPC-157 and TB-500 are discussed together under this name. Ratios, salts and formulations can differ between products.

Combining ingredients creates a different exposure; separate ingredient studies cannot establish mixture stability or clinical outcomes.

Benefits & claims

Interest centers on skin appearance, hair and tissue recovery.

What the evidence supports

  • GHK-Cu wound experiments and BPC/TB repair research test different substances and endpoints.
  • No verified human trial in the reviewed sources establishes that this three-ingredient blend improves skin or injury recovery.
  • The GLOW name does not establish a standardized pharmaceutical formulation.
Research areas
  • Interest centers on skin appearance, hair and tissue recovery.

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for GLOW blend. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • There is no standardized clinically validated ingredient ratio for this named blend.
  • No published ingredient regimen can be assembled into a supported regimen for this combination.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Human efficacy and adverse-event rates for the exact formulation
  • Chemical compatibility, stability and ingredient identity
  • Whether combined effects differ from the ingredients alone
GHK-Cu wound study in rats BPC-157 and TB-500 in rat tendon repair FDA: safety concerns for nominated bulk substances

Side effects & risks

  • FDA identifies route-specific immune-reaction and impurity concerns for injectable GHK-Cu and concerns for BPC-157 and TB-500.
  • Mixture-specific adverse effects, interactions and product stability are unknown.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

The reviewed sources do not establish efficacy or a human regimen for this exact combination. Ingredient-only experiments cannot show that the mixture is effective, synergistic or safer.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Pain: reported experiences

Mixed account · personal report

Skin changes alongside bruises and painful bumps

One author described better-looking skin and smaller pores during six weeks of GLOW, but also bruises, persistent bumps and pain. They said the marks were fading during a subsequent break.

Reported use in this account

Product
GLOW blend
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; precise route not stated
Duration
Six weeks before a break

The product was not independently verified, and skin changes were subjective. The account does not establish ingredient-specific effects or a typical reaction rate.

Read the original account
Mixed account · personal report

Better skin and fewer stomach complaints, with soreness

A third author described better-looking skin, fewer stomach problems and less neck or shoulder discomfort. In replies they also described bruising and soreness around some exposure sites.

Reported use in this account

Product
GLOW blend; ingredient ratio described but delivered amounts unresolved
Amount
Not specified clearly
Frequency
Twice daily
Route
Injection; precise route not established
Duration
Not specified clearly

The numerical amount in the thread was challenged and never clearly resolved; bottle contents and syringe markings do not establish ingredient doses. Other health changes were not controlled.

Read the original account

Approval status

There is no FDA-approved GLOW blend product or established approved use for this combination. Ingredient approvals, where present, do not transfer to the blend.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human efficacy and adverse-event rates for the exact formulation
  • Chemical compatibility, stability and ingredient identity
  • Whether combined effects differ from the ingredients alone

Summary

The GLOW name does not establish a standardized pharmaceutical formulation.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedGHK-Cu wound study in rats

    Animal wound-chamber study showing extracellular-matrix effects; not proof of human clinical benefit.

  2. pubmedBPC-157 and TB-500 in rat tendon repair

    Four-arm rat study; the abstract calls TB-500 synthetic thymosin beta-4, requiring an identity caveat.

  3. fdaFDA: safety concerns for nominated bulk substances

    Ingredient-specific uncertainties; compounding consideration is separate from FDA drug approval.

How we assess sources · Suggest a correction